Literature DB >> 16534644

[Intracerebral hemorrhage related to anticoagulant therapy].

H B Huttner1, E Jüttler, A Hug, M Köhrmann, P D Schellinger, T Steiner.   

Abstract

Intracerebral hemorrhage (ICH) is the most serious complication of oral anticoagulant therapy (OAT). The growing use of OAT has resulted in an increase of fatal ICH. The mortality rate is about 65%, and most of the surviving patients remain disabled. While improvements in the treatment of spontaneous ICH have recently been described, there are no internationally accepted guidelines for managing patients with OAT-ICH. Therefore, identifying effective treatments is essential for improving clinical outcome. This article reviews the epidemiology of OAT-ICH, its pathophysiology, and current treatment options and discusses open questions with particular respect to more recent pharmacological therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16534644     DOI: 10.1007/s00115-006-2063-5

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  88 in total

1.  Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary.

Authors:  P Hellstern; W M Halbmayer; M Köhler; R Seitz; G Müller-Berghaus
Journal:  Thromb Res       Date:  1999-08-15       Impact factor: 3.944

Review 2.  Managing oral anticoagulant therapy.

Authors:  J Ansell; J Hirsh; J Dalen; H Bussey; D Anderson; L Poller; A Jacobson; D Deykin; D Matchar
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

3.  What causes intracerebral hemorrhage during warfarin therapy?

Authors:  R G Hart
Journal:  Neurology       Date:  2000-10-10       Impact factor: 9.910

4.  Guidelines on oral anticoagulation: third edition.

Authors: 
Journal:  Br J Haematol       Date:  1998-05       Impact factor: 6.998

5.  Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex.

Authors:  J Oldenburg; B von Brederlow; A Fregin; S Rost; W Wolz; W Eberl; S Eber; E Lenz; R Schwaab; H H Brackmann; W Effenberger; U Harbrecht; L J Schurgers; C Vermeer; C R Müller
Journal:  Thromb Haemost       Date:  2000-12       Impact factor: 5.249

6.  Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk.

Authors:  T G Phan; M Koh; E F Wijdicks
Journal:  Arch Neurol       Date:  2000-12

7.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

Authors:  G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

8.  Prediction of functional outcome and in-hospital mortality after admission with oral anticoagulant-related intracerebral hemorrhage.

Authors:  J Berwaerts; R S Dijkhuizen; O J Robb; J Webster
Journal:  Stroke       Date:  2000-11       Impact factor: 7.914

Review 9.  Anaphylactic transfusion reactions.

Authors:  Colleen W Gilstad
Journal:  Curr Opin Hematol       Date:  2003-11       Impact factor: 3.284

Review 10.  Ultra-early hemostatic therapy for intracerebral hemorrhage.

Authors:  Stephan A Mayer
Journal:  Stroke       Date:  2003-01       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.